- Telehealth Visits
- Insurance plan information
James Maas, MD, PhD
Neurology • Movement Disorders Neurology- Telehealth Visits
- Insurance plan information
James Maas, MD, PhD
Neurology • Movement Disorders Neurology- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. James Maas is a neurologist who specializes in caring for patients with movement disorders, including Parkinson's disease, essential tremor and dystonia.
Maas' research centers on the role of proteins implicated in Parkinson's disease, as well as molecules that determine function in dopamine-producing neurons (the cells that die in people with Parkinson's).
Maas earned his medical degree from the Washington University School of Medicine in St. Louis, where he also completed a doctorate in neuroscience. He then completed a residency in neuroscience at UCSF. He belongs to the American Academy of Neurology.
Education & training
Board certification
- Psychiatry & Neurology, American Board of Psychiatry and Neurology
Fellowship
- Movement Disorders, University of CA at San Francisco School of Med
Residency
- Neurology, UCSF School of Medicine -GME
Internship
- Internal Medicine, UCSF School of Medicine -GME
Degree
- MD, Washington University School of Medicine in St. Louis
My expertise
Specialties
Locations
My research
Publications
Showing 1-6 of 33 reviews
- March 23, 20265 out of 5 Stars
I feel very confident with Dr Maas
- March 16, 20265 out of 5 Stars
Great listener
- March 9, 20265 out of 5 Stars
Dr. Maas is great!
- February 10, 20265 out of 5 Stars
Dr Maas is truly exceptional!
- January 26, 20265 out of 5 Stars
Dr. Maas is the very best in his expertise, listening and advice.
- January 12, 20265 out of 5 Stars
One of the best I have ever experienced
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.